<DOC>
	<DOCNO>NCT00006022</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . Combining bryostatin 1 interleukin-2 may kill tumor cell . PURPOSE : Randomized phase I trial study effectiveness interleukin-2 plus bryostatin 1 treat patient melanoma kidney cancer remove surgery .</brief_summary>
	<brief_title>Interleukin-2 Plus Bryostatin 1 Treating Patients With Melanoma Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose bryostatin 1 , administer conjunction low-dose interleukin-2 , maximize vitro interleukin-2- stimulated peripheral blood stem cell proliferation patient melanoma renal cell carcinoma . - Assess intermediate marker immune response patient treat regimen . - Determine tumor response , response duration , progression-free interval , survival patient treat regimen . OUTLINE : This randomize , double-blind study . Patients randomize one three bryostatin 1 dose level . Patients receive interleukin-2 subcutaneously daily day 1-5 bryostatin 1 IV 1 hour day 1 weekly 3 week . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 21 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm cutaneous mucosal melanoma renal cell carcinoma Unresectable disease No known uncontrolled CNS metastasis CNS metastasis allow recently irradiate know controlled PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Hemoglobin least 8 g/dL WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Absolute lymphocyte count least 1,000/mm^3 Hepatic : Total bilirubin great 1.5 mg/dL OR Conjugated bilirubin great 0.3 mg/dL AST great 2.5 time upper limit normal Renal : Creatinine great 2 mg/dL Cardiovascular : No myocardial infarction within past 6 month No uncontrolled hypertension , angina , congestive heart failure Other : Not pregnant nursing Fertile patient must use effective contraception 3 month study No known intolerance acetaminophen No primary secondary immunodeficiency No condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : At least 1 month since prior topical , systemic , inhaled corticosteroid No concurrent topical , systemic , inhaled corticosteroid Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>